Early blood test can predict treatment response and survival prospects in metastatic prostate cancer

FHS
October 7, 2024
11:45 pm

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 31, 2024

Improving the FDA-EMA parallel scientific advice program to advance complex generics

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics

August 20, 2024

Sen. Sanders launches probe of Novo’s Wegovy and Ozempic pricing

Sen. Bernie Sanders (I-VT) is ramping up his campaign against what he says are “outrageously high” list prices for Novo Nordisk’s weight loss and diabetes

April 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.